Medical Marijuana for Veterans: Democratic Congressman Confronts VA and DOD’s Denial of Crucial Treatment
In a groundbreaking move, a Democratic congressman has taken a strong stance against the U.S. Department of Veterans Affairs (VA) and the Department of Defense (DOD) for perpetuating a “misguided denial of services.” Rep. Earl Blumenauer (D-OR), co-chair of the Congressional Cannabis Caucus, has sent a compelling letter to VA Secretary Denis McDonough and DOD Secretary Lloyd Austin, urging them to reconsider their stance on the use of medical marijuana for veterans suffering from post-traumatic stress disorder (PTSD). He highlighted the significant benefits reported by veterans who have used medical cannabis, prompting him to push for a change in the current recommendations.
For decades, veterans across the country have shared their experiences, emphasizing how medical cannabis has been a life-saving treatment for PTSD. Blumenauer, along with other bipartisan supporters, underscored the importance of revisiting the antiquated and insufficient recommendation against the use of medical marijuana for PTSD patients. With 38 states having recognized the medical potential of marijuana for various conditions, many veterans have turned to cannabis as a substitute for prescription drugs, citing improved quality of life and reduced dependence on opioids and other medications, according to a recent survey.
Despite these advancements, the VA and DOD have a long-standing history of dismissing medical marijuana as a viable treatment option for those impacted by PTSD. They recently released joint clinical practice guidelines asserting that the potential serious adverse effects of cannabis outweigh any benefits. However, Blumenauer firmly pushes back against this claim, highlighting the need to acknowledge the reality of medical marijuana’s potential for treating PTSD.
President Joe Biden’s bipartisan legislation from last year, spearheaded by Blumenauer, sought to streamline research into cannabis, further emphasizing the importance of exploring its medical use. The congressman expressed his frustration with the federal prohibition on research that hinders the nation’s ability to study the health impacts of marijuana. Despite states forging ahead to establish medical marijuana programs, veterans within the VA system are denied access to this beneficial treatment option.
To address this disparity, the House recently approved an amendment to appropriations legislation, co-sponsored by Blumenauer and the bipartisan Cannabis Caucus co-chairs. This amendment seeks to prevent the enforcement of VA policies that prevent doctors from recommending medical marijuana for veterans, allowing them to have equal access to potential relief.
Moreover, the House passed another amendment on the same day, aimed at encouraging research into the therapeutic potential of psychedelics like psilocybin and MDMA, showcasing the growing momentum behind drug policy reform in Congress.
In parallel efforts, Democratic senators are working on a series of marijuana reform amendments for the National Defense Authorization Act (NDAA), including provisions that would permit veterans to use medical cannabis in states and territories where it is legal. The proposed amendments would also safeguard doctors who recommend medical marijuana for veterans and require the VA to support clinical trials investigating cannabis’s potential benefits in treating conditions like pain and PTSD.
The Senate Appropriations Committee has also entered the fray, releasing a report for its VA spending legislation that calls on the department to facilitate medical marijuana access for veterans and explore the therapeutic potential of psychedelics.
As the conversation around medical marijuana and psychedelic therapy continues to gain traction, it is evident that the time has come for the VA and DOD to become better partners in advocating for veterans’ well-being. Medical marijuana offers a promising treatment option for PTSD and other conditions afflicting our nation’s heroes, and it’s high time to prioritize their access to this potentially life-changing therapy.
